Your browser doesn't support javascript.
loading
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku, Filip; Kim, Tae Min; Iyer, Gopakumar; Spreafico, Anna; Elez, Elena; de Jonge, Maja; Yamamoto, Noboru; van der Wekken, Anthonie J; Ascierto, Paolo Antonio; Maur, Michela; Marmé, Frederik; Kiladjian, Jean-Jacques; Basu, Sumit; Baffert, Fabienne; Buigues, Amparo; Chen, Chi; Cooke, Vesselina; Giorgetti, Elisa; Kim, Jaeyeon; McCarthy, Fiona; Moschetta, Michele; Dummer, Reinhard.
Afiliação
  • Janku F; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: fjanku@me.com.
  • Kim TM; Seoul National University Hospital, Seoul, South Korea.
  • Iyer G; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  • Elez E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • de Jonge M; Erasmus Medical Center, Rotterdam, the Netherlands.
  • Yamamoto N; National Cancer Center Hospital, Tokyo, Japan.
  • van der Wekken AJ; University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Maur M; Oncology Unit, AOU Policlinico di Modena, Modena, Italy.
  • Marmé F; Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany.
  • Kiladjian JJ; Hospital Saint-Louis, Paris, France.
  • Basu S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Baffert F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Buigues A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Chen C; China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Cooke V; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Giorgetti E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Kim J; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • McCarthy F; Novartis Ireland Limited, Dublin, Ireland.
  • Moschetta M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Dummer R; University of Zürich, Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.
Eur J Cancer ; 196: 113458, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38039779
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Exantema / Neoplasias Pulmonares / Melanoma / Neoplasias Limite: Adult / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Exantema / Neoplasias Pulmonares / Melanoma / Neoplasias Limite: Adult / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2024 Tipo de documento: Article